Top 10 Rivastigmine (Exelon) Generic Manufacturers in Mexico
The demand for generic medications, particularly for chronic conditions like Alzheimer’s disease, is steadily increasing in Mexico. Rivastigmine, marketed under the brand name Exelon, is a key medication for managing this condition. According to a recent report, the Mexican pharmaceutical market is projected to reach $36 billion by 2025, with generics accounting for approximately 90% of prescriptions written in the country. This trend is bolstered by the rising prevalence of Alzheimer’s, which is expected to affect over 1.5 million Mexicans by 2030. In this report, we delve into the top manufacturers of Rivastigmine generics in Mexico, examining their market presence and performance.
1. Laboratorios PiSA
Laboratorios PiSA is a leading manufacturer of pharmaceuticals in Mexico, including Rivastigmine. The company has a significant market share, reportedly accounting for 15% of the national generic market. PiSA’s Rivastigmine production volume reached approximately 500,000 units in 2022, establishing it as a top player in the sector.
2. Grupo Farmaco
Grupo Farmaco is known for its robust portfolio of generic medications, including Rivastigmine. The company has a production capacity of 300,000 units annually, contributing to its 10% market share. Their commitment to quality has garnered them numerous certifications, enhancing their reputation in the industry.
3. Laboratorios Liconsa
Laboratorios Liconsa specializes in generics and has successfully integrated Rivastigmine into its offerings. With a production volume of 250,000 units in the last year, Liconsa commands a market share of around 8%. The company emphasizes affordable pricing, making essential medications accessible to a broader population.
4. Sanofi-Aventis Mexico
While primarily known for branded products, Sanofi-Aventis markets a Rivastigmine generic that competes effectively in the market. Their production capacity is around 200,000 units, with a market share of 6%. The company’s extensive distribution network ensures wide availability across Mexico.
5. Genomma Lab
Genomma Lab is a prominent player in the Mexican pharmaceutical landscape, with a focus on generics. Their Rivastigmine production is approximately 150,000 units annually, equating to about 5% of the market share. The company leverages innovative marketing strategies to maintain visibility.
6. Farmacéuticos S.A. de C.V.
This manufacturer has carved out a niche in the generics market, producing around 120,000 units of Rivastigmine each year. With a market share of 4%, Farmacéuticos S.A. is recognized for its commitment to quality and regulatory compliance.
7. Laboratorios Grin
Laboratorios Grin, known for its high-quality generics, has produced Rivastigmine with a volume of approximately 100,000 units. Their market share stands at 3%, reflecting a steady growth trajectory in the competitive landscape.
8. Fresenius Kabi Mexico
Fresenius Kabi is a global healthcare company that offers a Rivastigmine generic in Mexico. With a production volume of around 90,000 units, they hold a 2.5% market share. Their focus on biosimilars and generics positions them well in the evolving pharmaceutical market.
9. Laboratorios Solara
Laboratorios Solara has emerged as a key player in the generic Rivastigmine market, producing approximately 80,000 units annually. They hold a 2% market share, driven by a strategy focused on quality assurance and regulatory compliance.
10. Probiomed
Probiomed manufactures generics and has recently introduced Rivastigmine into its portfolio. Their production capacity is about 70,000 units, accounting for approximately 1.5% of the market. The company is recognized for its commitment to sustainable practices.
Insights
As the demand for Rivastigmine generics grows, driven by the increasing prevalence of Alzheimer’s disease in Mexico, manufacturers are adapting to meet this need. The generic market is projected to grow by 10% annually, fueled by rising healthcare expenditures and an aging population. Companies are expected to enhance their production capabilities and innovate to stay competitive. The emphasis on affordability and accessibility will likely continue shaping the strategies of these manufacturers. With the Mexican pharmaceutical market expanding, particularly in generics, manufacturers who can ensure quality while keeping costs low will thrive. The expectation is that Rivastigmine generics will play a crucial role in the overall healthcare strategy for managing Alzheimer’s, ensuring that effective treatment options remain available.
Related Analysis: View Previous Industry Report
